Neuromodulation of the Hippocampus to Reduce Intrusive Re-Experiencing in PTSD: A Randomized Controlled Trial

Exclusion Criteria

• •Meeting a diagnosis of Complex PTSD or personality disorder.
• •Psychotic disorder, bipolar disorder, or a developmental neuropsychological disorder (autism, mental retardation).
• •Use of psychiatric medications (except for the medications listed in section 4.a of the study protocol if the medication dosage is stable in the last three months and does not change during the study.
• •Exclusion rules in TMS research (see guidelines).
• •Use of the following drugs: imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma- hydroxybutyrate (GHB), alcohol, theophylline
• •Epilepsy or use of anti-epileptic drugs.
• •Traumatic head injuries or head surgery.
• •Implanted metallic body (except fillings/amalgam bites/orthodontic fixations approved for MRI), electrodes or a pacemaker.
• •Migraines
• •Pregnant women
• •Hearing problems
• •Drinking alcohol 24 hours before the TMS session
• •Repeated episodes of fainting with loss of consciousness and/or an event of fainting with loss of consciousness in the past year.